Toggle Navigation
Each
Pod
Each
Pod
Podcasts
Episodes
Genres
Login
Oncology Times - OncTimes Talk
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition
Author
Oncology Times
Published
Thu 16 Nov 2023
Episode Link
https://traffic.libsyn.com/secure/otbroadcastsarchives/OT-POD_EP50_11092023.mp3
Share to:
